ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details: | |
Date: | Thursday, May 8, 2025 |
Time: | 3:30 p.m. CST / 4:30 p.m. EST |
Location: | |
U.S. dial-in | +1 (800) 715-9871 |
International dial-in: | +1 (646) 307-1963 |
Conference ID: | 6342275 |
A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures will be available on the Investor Relations section of Solventum's website.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.
| Last Trade: | US$73.09 |
| Daily Change: | 0.43 0.59 |
| Daily Volume: | 786,883 |
| Market Cap: | US$12.670B |
August 07, 2025 March 12, 2025 February 27, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
